Anita Csizmarik

Anita Csizmarik

Auto-generated profile, based on publicly available information

Anita Csizmarik

Department of Urology Semmelweis University Budapest, Hungary

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2020 in BJU International
Verified
Journal Article
Closed access
PDF file
TSTibor Szarvas
Tibor Szarvas
ACAnita Csizmarik
Anita Csizmarik
TFTamás Fazekas
Tamás Fazekas
AHAndrás Hüttl
András Hüttl
PNPéter Nyirády
Péter Nyirády
GKGero Kramer
Gero Kramer

21 June 2022 in International Journal of Cancer
Verified
Journal Article
Open access
ACAnita Csizmarik
Anita Csizmarik
DKDávid Keresztes
Dávid Keresztes
NNNikolett Nagy
Nikolett Nagy
TBThilo Bracht
Thilo Bracht
BSBarbara Sitek
Barbara Sitek
TSTibor Szarvas
Tibor Szarvas
Enzalutamide (ENZA) is a frequently used therapy in metastatic castration-resistant prostate cancer (mCRPC). Baseline or acquired resistance to ENZA have been observed, but the molecular mechanisms of resistance are poorly understood. We aimed to identify proteins involved in ENZA resistance and to find therapy-predictive serum markers. We performed comparative proteome analyses on ENZA-sensitive parental (LAPC4, DuCaP) and -resistant prostate cancer cell lines (LAPC4-ENZA, DuCaP-ENZA) using liquid chromatography tandem mass spectrometry (LC-MS/MS). The top four most promising candidate markers were selected using bioinformatic approaches. Serum concentrations of selected markers (ALCAM, AGR2, NDRG1, IDH1) were measured in pretreatment samples of 72 ENZA-treated mCRPC patients using ELISA. In addition, ALCAM serum levels were measured in 101 Abiraterone (ABI) and 100 Docetaxel (DOC)-treated mCRPC patients' baseline samples. Results were correlated with clinical and follow-up data. The functional role of ALCAM in ENZA resistance was assessed in vitro using siRNA. Our proteome analyses revealed 731 significantly differentially abundant proteins between ENZA-sensitive and -resistant cells and our filtering methods identified four biomarker candidates. Serum analyses of these proteins revealed only ALCAM to be associated with poor patient survival. Furthermore, higher baseline ALCAM levels were associated with poor survival in ABI- but not in DOC-treated patients. In LAPC4-ENZA resistant cells, ALCAM silencing by siRNA knockdown resulted in significantly enhanced ENZA sensitivity. Our analyses revealed that ALCAM serum levels may help to identify ENZA- and ABI-resistant patients and may thereby help to optimize future clinical decision-making. Our functional analyses suggest the possible involvement of ALCAM in ENZA resistance.